Combivent (ipratropium/salbutamol) / Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
 17 Diseases   2 Trials   2 Trials   88 News 


12»
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Combivent (ipratropium/salbutamol) / Boehringer Ingelheim, Fasenra (benralizumab) / AstraZeneca
    A CASE OF INTRACTABLE WHEEZE IN A PATIENT WITH SEVERE ASTHMA DESPITE BIOLOGIC THERAPY (Convention Center Exhibit Hall: Rapid Fire Area 1A) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_4860;    
    At that time, he was also on tezepelumab having received twelve months of treatment...He reported having five exacerbations in the last year requiring prednisone...IgE was 19 and peripheral eosinophils were as high as 0.4 x10^9/L before starting benralizumab... This case highlights the importance of recognizing ECAC as a potential confounder for patients with severe, uncontrolled asthma not responding to conventional therapy.
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim, nebulized fentanyl citrate / Boehringer Ingelheim
    Trial completion, Trial completion date, Metastases:  Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) -  Apr 13, 2023   
    P4,  N=20, Completed, 
    This case highlights the importance of recognizing ECAC as a potential confounder for patients with severe, uncontrolled asthma not responding to conventional therapy. Suspended --> Completed | Trial completion date: Dec 2022 --> Mar 2023
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim, nebulized fentanyl citrate / Boehringer Ingelheim
    Trial completion date, Trial primary completion date, Metastases:  Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) -  Apr 22, 2022   
    P4,  N=17, Suspended, 
    Suspended --> Completed | Trial completion date: Dec 2022 --> Mar 2023 Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim
    Journal:  Effect of IFN-α and other commonly used nebulization drugs in different nebulization methods on the resistance of breathing circuit filters under invasive mechanical ventilation. (Pubmed Central) -  Mar 15, 2022   
    The remaining groups received jet nebulized or vibrating nebulized with either normal saline, Combivent, Amphotericin B, or IFN-α at a frequency of once every 12 hours separately and were removed from the breathing circuit after 24 hours...The effect of jet nebulization and vibrating mesh nebulization on the resistance of breathing filters showed no significant statistical difference. Jet nebulization with IFN-α significantly increased the resistance of the breathing filter within 24 hours and there was no significant difference in filter resistance between jet nebulization and vibrating mesh nebulization of IFN-α or Amphotericin B.
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim, nebulized fentanyl citrate / Boehringer Ingelheim
    Trial primary completion date, Metastases:  Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) -  May 26, 2021   
    P4,  N=17, Suspended, 
    Jet nebulization with IFN-α significantly increased the resistance of the breathing filter within 24 hours and there was no significant difference in filter resistance between jet nebulization and vibrating mesh nebulization of IFN-α or Amphotericin B. Trial primary completion date: Mar 2021 --> Sep 2021
  • ||||||||||  Xolair (omalizumab) / Roche, Novartis, Onbrez (indacaterol) / Novartis
    Journal:  Drugs for asthma. (Pubmed Central) -  Jan 26, 2021   
    Trial primary completion date: Mar 2021 --> Sep 2021 No abstract available
  • ||||||||||  Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
    Journal:  Drugs for COPD. (Pubmed Central) -  Dec 30, 2020   
    Trial primary completion date: Oct 2020 --> Mar 2021 No abstract available
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim, nebulized fentanyl citrate / Boehringer Ingelheim
    Trial completion date, Trial suspension, Trial primary completion date, Metastases:  Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) -  Sep 17, 2020   
    P4,  N=17, Suspended, 
    No abstract available Trial completion date: Aug 2020 --> Aug 2022 | Recruiting --> Suspended | Trial primary completion date: Jun 2020 --> Oct 2020
  • ||||||||||  Combivent Respimat (ipratropium/albuterol metered spray inhalation) / Boehringer Ingelheim, Combivent (ipratropium/salbutamol) / Boehringer Ingelheim
    Journal:  Strategies to conserve salbutamol pressurized metered-dose inhaler stock levels amid COVID-19 drug shortage. (Pubmed Central) -  Aug 26, 2020   
    These strategies include reprocessing used or expired pMDIs, using intravenous salbutamol and other short acting inhalers when available, and prescribing maintenance inhalers to prevent over usage of salbutamol pMDIs. We also highlight the important role of physicians and pharmacists in optimizing medication therapies to ensure adequate supplies.
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim, nebulized fentanyl citrate / Boehringer Ingelheim
    Trial completion date, Trial primary completion date, Metastases:  Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) -  Jan 13, 2020   
    P4,  N=17, Recruiting, 
    The mixing did not influence the particle size, distribution, or delivery compatibility of the mixtures. Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Jun 2020
  • ||||||||||  danirixin (GSK1325756) / GSK
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, HEOR:  A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) -  Feb 6, 2019   
    P2,  N=54, Terminated, 
    Recruiting --> Completed | N=200 --> 62 N=100 --> 54 | Trial completion date: Mar 2020 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: Mar 2020 --> Nov 2018; Terminated based on lack of efficacy seen in participants taking danirixin in dose ranging study and Sponsor decision to stop development of danirixin for COPD
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim, nebulized fentanyl citrate / Boehringer Ingelheim
    Trial completion date, Trial primary completion date, Metastases:  Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) -  Sep 25, 2018   
    P4,  N=17, Recruiting, 
    N=100 --> 54 | Trial completion date: Mar 2020 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: Mar 2020 --> Nov 2018; Terminated based on lack of efficacy seen in participants taking danirixin in dose ranging study and Sponsor decision to stop development of danirixin for COPD Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
  • ||||||||||  danirixin (GSK1325756) / GSK
    Trial completion date, Trial primary completion date, HEOR:  A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) -  Sep 5, 2018   
    P2,  N=100, Recruiting, 
    Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial completion date: Oct 2019 --> Mar 2020 | Trial primary completion date: Oct 2019 --> Mar 2020
  • ||||||||||  danirixin (GSK1325756) / GSK
    Trial completion date, Trial primary completion date, HEOR:  A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) -  Apr 20, 2018   
    P2,  N=100, Recruiting, 
    Trial completion date: Oct 2019 --> Mar 2020 | Trial primary completion date: Oct 2019 --> Mar 2020 Trial completion date: Jun 2019 --> Oct 2019 | Trial primary completion date: Jun 2019 --> Oct 2019
  • ||||||||||  danirixin (GSK1325756) / GSK
    Trial completion date, Trial primary completion date, HEOR:  A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) -  Feb 9, 2018   
    P2,  N=100, Recruiting, 
    Trial completion date: Jun 2019 --> Oct 2019 | Trial primary completion date: Jun 2019 --> Oct 2019 Trial primary completion date: Mar 2019 --> Jun 2019 | Trial completion date: Mar 2019 --> Jun 2019
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim
    New P3 trial:  Efficacy and Safety of Combivent (clinicaltrials.gov) -  Jul 8, 2014   
    P3,  N=47, Terminated, 
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim
    New P2 trial:  Combivent (clinicaltrials.gov) -  Jul 8, 2014   
    P2,  N=7, Terminated, 
  • ||||||||||  Combivent (ipratropium/salbutamol) / Boehringer Ingelheim
    New P1 trial:  Safety and Tolerability of COMBIVENT (clinicaltrials.gov) -  Jun 27, 2014   
    P1,  N=12, Completed,